☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
a TP53 Mutation
Aprea's APR-246 Receives the US FDA's Breakthrough Therapy Designation for Myelodysplastic Syndromes with a TP53 Mutation
January 30, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.